Results 31 to 40 of about 14,163 (275)

Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study

BMC Cardiovascular Disorders, 2020
Background Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin inhibitors have shown beneficial effects in patients with heart failure.
Ik Jun Choi, Sungmin Lim, Youngdeok Hwang, Dongjae Lee, Won Jik Lee, Kwan Yong Lee, Mi-Jeong Kim, Doo Soo Jeon   +7 more
doaj   +1 more source

Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure

European Journal of Heart Failure, 2022
Patients with heart failure are at higher risk of progression to end‐stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin–neprilysin inhibition in a pooled analysis of 13 195 patients with heart ...
Finnian R. Mc Causland, M. Lefkowitz, B. Claggett, M. Packer, M. Senni, M. Gori, P. Jhund, M. McGrath, J. Rouleau, V. Shi, K. Swedberg, M. Vaduganathan, F. Zannad, M. Pfeffer, M. Zile, J. McMurray, S. Solomon   +16 more
semanticscholar   +1 more source

Neprilysin, obesity and the metabolic syndrome [PDF]

International Journal of Obesity, 2010
Neprilysin (NEP), a zinc metalloendopeptidase, has a role in blood pressure control and lipid metabolism. The present study tested the hypothesis that NEP is associated with insulin resistance and features of the metabolic syndrome (MetS) in a study of 318 healthy human subjects and in murine obesity, and investigated NEP production by adipocytes in ...
Standeven, K F, Hess, K, Carter, A M, Rice, G I, Cordell, P A, Balmforth, A J, Lu, B, Scott, D J, Turner, A J, Hooper, N M, Grant, P J   +10 more
openaire   +4 more sources

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus

Frontiers in Medicine, 2022
Chronic kidney disease (CKD) is a global public health problem, and cardiovascular disease is the most common cause of death in patients with CKD.
L. Gan, Xiaoxi Lyu, Xiangdong Yang, Zhanzheng Zhao, Ying Tang, Yuan-han Chen, Ying Yao, F. Hong, Zhong-min Xu, Jihong Chen, L. Gu, H. Mao, Y. Liu, Jing-Ting Sun, Zhu Zhou, Xuanyi Du, Hong Jiang, Yong Li, N. Sun, Xinlin Liang, Li Zuo   +20 more
semanticscholar   +1 more source

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

New England Journal of Medicine, 2014
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.
J. McMurray, M. Packer, Akshay S. Desai, J. Gong, M. Lefkowitz, A. Rizkala, J. Rouleau, V. Shi, S. Solomon, K. Swedberg, M. Zile   +10 more
semanticscholar   +1 more source

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?

Biology, 2022
Simple Summary Active BNP-32, less active proBNP-108, and inactive N-terminal proBNP-76 all circulate in the blood. The circulating protease neprilysin has lower substrate specificity for BNP than ANP, while proBNP and N-terminal proBNP are not degraded ...
T. Nishikimi, Y. Nakagawa
semanticscholar   +1 more source

Neprilysin as a Biomarker: Challenges and Opportunities

Cardiac Failure Review, 2020
Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care.
Pavo, Noemi, Prausmüller, Suriya, Bartko, Philipp E, Goliasch, Georg, Hülsmann, Martin   +4 more
openaire   +5 more sources

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

New England Journal of Medicine, 2019
BACKGROUND The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction.
S. Solomon, J. McMurray, I. Anand, J. Ge, C. Lam, A. Maggioni, F. Martinez, M. Packer, M. Pfeffer, B. Pieske, M. Redfield, J. Rouleau, D. V. van Veldhuisen, F. Zannad, M. Zile, Akshay S. Desai, Brian Claggett, P. Jhund, S. Boytsov, J. Comín-Colet, J. Cleland, H. Düngen, E. Goncalvesova, T. Katova, J. K. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, Sanjiv J. Shah, Jingmin Zhou, A. Rizkala, J. Gong, V. Shi, M. Lefkowitz   +33 more
semanticscholar   +1 more source

Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. [PDF]

, 2017
Aims: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor–neprilysin inhibitor (
Baranello, Cannon, Chitnis, Cohn, Debiec, Elkahloun, Fabian Chen, Jane A. Cannon, Jean L. Rouleau, Jianjian Gong, John J.V. McMurray, Karl Swedberg, Kjekshus, Krum, Lambert, Langenickel, Lars Køber, Li Shen, Martin P. Lefkowitz, Matthews, McMurray, McMurray, McMurray, McMurray, McMurray, McMurray, Michael R. Zile, Milton Packer, Nalivaeva, Packer, Packer, Pandharipande, Pardeep S. Jhund, Qiu, Satizabal, Scott D. Solomon, Sorrentino, Søren L. Kristensen, Valenti, Victor C. Shi   +39 more
core   +3 more sources